Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 912, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174580
Keywords
Gliomas; Temozolomide; Pharmacogenomics; Gene polymorphism
Categories
Funding
- Beijing Health Alliance Charitable Foundation [WS016E]
- National Natural Science Foundation of China [81803542, 81803516]
- Shanghai Municipal Health Commission [20184Y0102]
Ask authors/readers for more resources
Recent advances in pharmacogenomics have opened up possibilities for predicting temozolomide response in gliomas. However, individual differences in response must be taken into account, as genetic polymorphisms can impact temozolomide's pharmacokinetics and anti-tumor effects. This review summarizes pharmacogenomic studies of temozolomide in gliomas, laying the groundwork for personalized chemotherapy.
Recent developments in pharmacogenomics have created opportunities for predicting temozolomide response in gliomas. Temozolomide is the main first-line alkylating chemotherapeutic drug together with radiotherapy as standard treatments of high-risk gliomas after surgery. However, there are great individual differences in temozolomide response. Besides the heterogeneity of gliomas, pharmacogenomics relevant genetic polymorphisms can not only affect pharmacokinetics of temozolomide but also change anti-tumor effects of temozolomide. This review will summarize pharmacogenomic studies of temozolomide in gliomas which can lay the foundation to personalized chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
